Check in with the scientists that YOU fund to see the latest innovations in breast cancer research:
Sunnybrook Health Science Centre
Dr Gregory Czarnota PhD, MD Scientist
Dr. Czarnota is conducting research focused on using ultrasound imaging and spectroscopy at conventional and high frequencies to detect apoptosis and other forms of cell death in response to chemotherapy and radiation therapy. In addition to being a scientist in the imaging discipline he is an MD in the department of radiation oncology with applied research in breast cancer patients. His basic science research interests include studies in biochemistry, chromatin biology, biophysics, medicine and oncology.
Dr. Czarnota's exciting new research involves the use of microbubbles and ultrasound to effectively target tumours and enhance treatment in breast cancer patients.
London Health Sciences Centre
Under the direction of Dr. Ann F. Chambers, PhD, the Pamela Greenaway Kohlmeier Translational Breast Cancer Research Unit (TBCRU) at the London Regional Cancer Program is awarded $500,000 annually to support breast cancer research.
More Stories from Your Researchers
“Thanks to the Breast Cancer Society of Canada, I have received a scholarship to perform some exciting research at London Health Sciences Centre’s London Regional Cancer Program. Originally trained as a medical doctor in Colombia, I am now carrying out my graduate studies with translational scientist Dr. Alison Allan, studying a very specific type of aggressive breast cancer cells called ‘cancer stem cells’ that are responsible for distant spread (metastasis) and therapy resistance in breast cancer.”
-Dr. Mauricio Rodriguez-Torres, Translational Breast Cancer Research Studentship, 2012-2013
"Thanks to the Breast Cancer Society of Canada, I have received funding to perform some incredible research in Dr. Peter Rogan's laboratory in the Department of Biochemistry at Western University. I am analyzing the genomes of breast cancer samples from The Cancer Genome Atlas to better understand which genes are essential for tumor survival. My goal is to better predict chemotherapy response for drugs that target the products of these genes.”
- Stephanie Dorman, Translational Breast Cancer Research Studentship, 2011-2014
"Thanks to funding from the Breast Cancer Society of Canada our team was able to build a program of research for supportive and palliative care for women with advanced breast cancer. These funds have enabled our team to build, share and critically assess a set of very innovative new research directions for this challenging stage of life for many women.”
- Grace Johnston, breast cancer survivor, Dalhousie University, Halifax NS
"Microbubbles are microscopic agents that can perturb the blood vessels inside tumors. When these bubbles are put into a beam of ultrasound, they resonate, making the tumors very sensitive to chemotherapy or radiation therapy. We see an increase in accumulation of chemotherapy by up to 20 times. With radiation, we find the tumors become 20% - 40% more sensitive to the effects of radiation. The $1 million investment by the Breast Cancer Society of Canada is going to allow our team to scale up these treatments by moving them out of the laboratory, into the breast cancer patients.”
- Dr. Greg Czarnota Radiation oncologist, Sunnybrook Health Sciences Centre, Toronto ON
"The Breast Cancer Society of Canada occupies a unique niche in the scientific funding spectrum for clinical breast cancer research in Canada which allows us here in Alberta to provide grants for 'seed funding.' Young clinical investigators initiating appropriate breast cancer projects who have good ideas but lack start-up funds can apply for funding for their demonstration or pilot project. Once the project is up and running the investigators can then apply to other agencies for continuation funding with a base of data supporting their applications. For example, Dr. Kay Egan was able to initiate a study of the role of the ‘CXCL/CXCR 4 axis’ in the process of spread of bone metastases from breast cancer and the possibility of testing inhibitors of this axis in mice."
- Dr. Alexander Paterson, Tom Baker Cancer Centre, Calgary AB